ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, announced its participation in three investor conferences this September. The events include the Citi’s 17th Annual Biopharma Conference on September 8 at 2:40 p.m. ET, the Wells Fargo Healthcare Conference on September 9 at 8:35 a.m. ET, and the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 7:00 a.m. ET. Webcasts of the discussions will be available on the company’s website and accessible for 90 days post-event.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September:

• Citi’s 17^th Annual Biopharma Conference – Targeted oncology panel discussion on Thursday, September 8, 2022, at 2:40 p.m. ET
  
  
• Wells Fargo Healthcare Conference – Participating in fireside chat on Friday, September 9, 2022, at 8:35 a.m. ET
  
  
• H.C. Wainwright 24^th Annual Global Investment Conference – Presenting company overview on Monday, September 12, 2022, at 7:00 a.m. ET
  

Webcasts of the panel discussion and presentations will be available through the investor section of the company’s website at www.oricpharma.com. Replays of webcasts will be available for 90 days following the events.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

What conferences is ORIC Pharmaceuticals participating in September 2022?

ORIC Pharmaceuticals will participate in Citi’s 17th Annual Biopharma Conference on September 8, the Wells Fargo Healthcare Conference on September 9, and the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

What is the schedule for ORIC Pharmaceuticals' investor conferences?

The schedule is as follows: Citi’s 17th Annual Biopharma Conference on September 8 at 2:40 p.m. ET, Wells Fargo Healthcare Conference on September 9 at 8:35 a.m. ET, and H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 7:00 a.m. ET.

Where can I find webcasts of ORIC Pharmaceuticals' conference presentations?

Webcasts of ORIC Pharmaceuticals' presentations will be available in the investor section of their website and can be accessed for 90 days following the events.

What is the focus of ORIC Pharmaceuticals?

ORIC Pharmaceuticals focuses on developing treatments that address mechanisms of therapeutic resistance in cancer.

What are the key product candidates of ORIC Pharmaceuticals?

ORIC's key product candidates include ORIC-533 for multiple myeloma, ORIC-114 for genetically defined cancers, and ORIC-944 for prostate cancer.